A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)
Sponsor: |
Pronai Therapeutics |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAP4516 |
U.S. Govt. ID: |
NCT02378038 |
Contact: |
Nicole Lamanna: 646-317-5205 / nl2129@columbia.edu |
This study is for patients with Richter's transformation (RT). The purpose of this study is to see if a new type of investigational drug called PNT2258 that may be effective in blocking the "on" signal to cancer cells, eventually causing them to die. We are trying to see if PNT2258 provides evidence of anti-tumor effect by measuring what happens to tumors after exposure to PNT2258.
This study is closed
Investigator
Nicole Lamanna, MD
Do you have a confirmed diagnosis of Richter's transformation (RT) from chronic lymphocytic leukemia/small lymphocytic lymphoma? |
Yes |
No |